Long-term wear dressing with slough cleaning holes
Patent Information
- Application Number
- JP2023527317
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-11
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-11-10
AI Technical Summary
Existing wound treatment systems, particularly those using negative pressure therapy and instillation therapy, face challenges in effectively removing debris such as necrotic tissue and promoting long-term tissue growth while minimizing tissue trauma and preventing granulation tissue ingrowth.
A dressing system with a first layer having through holes and a second layer with fluid restrictions and perforations, designed to be used with a negative pressure source, allows for debris removal and tissue growth promotion by aligning perforations with through holes under pressure, inhibiting tissue ingrowth.
The system effectively removes debris and promotes tissue growth by creating ports for fluid removal while preventing tissue ingrowth, enabling extended wear and reducing patient discomfort and treatment delays.
Abstract
Description
[Technical Field]
[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 112,240, filed November 11, 2020, the entire contents of which are incorporated herein by reference.
[0002] The present invention as defined in the accompanying claims relates generally to tissue treatment systems and particularly, but not exclusively, to dressings for tissue treatment and methods of using dressings for tissue treatment. [Background technology]
[0003] Clinical studies and clinical practice have shown that reducing pressure in the vicinity of a tissue site can enhance and accelerate the growth of new tissue at the tissue site. While the applications of this phenomenon are numerous, it has proven particularly advantageous for treating wounds. Regardless of the cause of the wound, whether traumatic, surgical, or otherwise, proper care of the wound is critical to the outcome. Treatment of wounds or other tissues with reduced pressure may generally be referred to as "negative pressure therapy," but is also known by other names, including, for example, "negative pressure wound therapy," "reduced pressure therapy," "vacuum therapy," "negative pressure closure," and "topical negative pressure." Negative pressure therapy can provide many benefits, including epithelial and subcutaneous tissue migration, improved blood flow, and microdeformation of tissue at the wound site. Collectively, these benefits can promote the growth of granulation tissue and reduce healing time.
[0004] It is also widely accepted that cleansing a tissue site can be highly beneficial to new tissue growth. For example, a wound or cavity can be flushed with a therapeutic liquid solution. These actions are commonly referred to as "irrigation" and "lavage," respectively. "Dripping" is another action that generally refers to the process of slowly introducing fluid into a tissue site, leaving the fluid there for a prescribed period of time, and then removing the fluid. For example, dripping a topical therapeutic solution onto a wound bed, combined with negative pressure therapy, can further promote wound healing by agitating soluble contaminants in the wound bed and removing infectious materials. As a result, the soluble bacterial load can be reduced, contaminants can be removed, and the wound can be cleansed.
[0005] While the clinical benefits of negative pressure and / or drip therapy are widely known, improvements in treatment systems, components, and processes can benefit healthcare providers and patients. Summary of the Invention
[0006] New and useful systems, devices, and methods for treating tissue in a negative pressure therapy environment are set forth in the accompanying claims. Exemplary embodiments are also provided to enable one of ordinary skill in the art to make and use the claimed subject matter.
[0007] For example, in some embodiments, a dressing for treating a tissue site is described. The dressing can include a first layer having a first side and a second side. The first layer can include a plurality of through-holes extending through the first layer from the first side to the second side. The dressing can include a second layer configured to be disposed adjacent to the first side of the first layer. The second layer can include a plurality of fluid restriction portions disposed therein. The second layer can also include a plurality of perforations disposed therein and configured to be aligned with the plurality of through-holes.
[0008] Also described herein are methods of manufacturing a dressing for a tissue site, and some exemplary embodiments include providing a first layer and forming a plurality of through-holes in the first layer. A second layer can be provided, and a plurality of fluid restriction portions and a plurality of perforations can be formed in the second layer. The second layer can be positioned adjacent to the first layer.
[0009] Alternatively, other exemplary embodiments may describe a system for treating a tissue site using reduced pressure. The system may include a dressing, a sealing member disposed over the dressing and configured to be sealed to tissue surrounding the tissue site, and a reduced pressure source configured to be fluidly coupled to the dressing through the sealing member. The dressing may include a debridement tool having a first side and a second side, and a contact layer configured to be disposed adjacent to the first side of the debridement tool. The debridement tool may include a plurality of openings extending through the debridement tool from the first side to the second side. The contact layer may include a plurality of fenestrations and a plurality of openings. The plurality of openings may be configured to align with the plurality of openings.
[0010] Methods of treating a tissue site are also described herein, and some exemplary embodiments include placing a dressing at a tissue site. The dressing can include a first layer and a second layer. The first layer can have a first side and a second side, and the second layer can be configured to be positioned adjacent to the first side of the first layer. The first layer can have a plurality of through-holes extending therethrough from the first side to the second side. The second layer can have a plurality of fluid restrictors and a plurality of perforations. The perforations can be configured to be aligned with the perforations. A negative pressure source can be fluidly coupled to the dressing, and negative pressure from the negative pressure source can be applied to the dressing. A periphery of each of the perforations can extend into the perforations to create a port through the first layer. Fluid can be drawn through the port.
[0011] The objects, advantages and preferred modes of making and using the claimed subject matter will be best understood by referring to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments. [Brief explanation of the drawings]
[0012] [Figure 1] FIG. 1 is a functional block diagram of an exemplary embodiment of a treatment system capable of providing negative pressure and instillation treatment to a tissue site in accordance with the present disclosure. [Figure 2] FIG. 2 is an assembled view of an example tissue interface of FIG. 1 showing additional details that may be relevant to some embodiments. [Figure 3] FIG. 3 is a plan view of a first layer of the tissue interface of FIG. 2 showing additional details that may be relevant to some embodiments. [Figure 4] FIG. 4 is a detailed view of the first layer taken at reference FIG. 4 of FIG. 3 showing additional details that may be relevant to some embodiments. [Figure 5] FIG. 5 is a plan view of a second layer of the tissue interface of FIG. 2 showing additional details that may be relevant to some embodiments. [Figure 6] FIG. 6 is a detailed view of the second layer taken at reference 6 of FIG. 5, showing additional details that may be relevant to some embodiments. [Figure 7] FIG. 7 is a detailed view of the second layer taken at reference 7 of FIG. 6, showing additional details that may be relevant to some embodiments. [Figure 8] FIG. 8 is a cross-sectional view of the assembled tissue interface of FIG. 2 taken along line 8-8, showing additional details that may be relevant to some embodiments. [Figure 9] FIG. 9 is a cross-sectional view of the assembled tissue interface of FIG. 2 taken along line 8-8 during negative pressure therapy, showing additional details that may be relevant to some embodiments. [Figure 10] FIG. 10 is a detailed view of a portion of the tissue interface of FIG. 9 showing additional details of the operation of the tissue interface during negative pressure therapy. [Figure 11]FIG. 11 is a perspective view of the second layer of FIG. 2 showing additional details that may be relevant to some embodiments. [Figure 12] FIG. 12 is a cross-sectional view of the second layer of FIG. 11 taken along line 12-12, showing additional details that may be relevant to some embodiments. [Figure 13] FIG. 13 is an assembly view of another example of the tissue interface of FIG. 1, showing additional details that may be relevant to some embodiments. [Figure 14] FIG. 14 is a cross-sectional view of the assembled tissue interface of FIG. 13 taken along line 14-14, showing additional details that may be relevant to some embodiments. DETAILED DESCRIPTION OF THE INVENTION
[0013] The following description of exemplary embodiments provides information to enable one skilled in the art to make and use the claimed subject matter, but may omit certain details already known in the art. Thus, the following detailed description is to be construed as illustrative and not limiting.
[0014] Example embodiments may also be described herein with reference to the spatial relationships between or orientation of various elements as shown in the accompanying drawings. Generally, such relationships or orientations are in a frame of reference that is consistent with or relative to a patient in a position to receive treatment. However, those skilled in the art will understand that this frame of reference is not a strict requirement and is merely for convenience of explanation.
[0015] FIG. 1 is a simplified functional block diagram of an exemplary embodiment of a treatment system 100 according to the present disclosure, which is capable of providing negative pressure therapy using instillation of a topical treatment solution to a tissue site.
[0016] In this context, the term "tissue site" broadly refers to a wound, defect, or other treatment target on or within tissue, including, but not limited to, a surface wound, bone tissue, adipose tissue, muscle tissue, nerve tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendon, or ligament. The term "tissue site" may also refer not necessarily to any area of tissue where there is a wound or defect, but instead to an area where it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that can be harvested and transplanted. A surface wound, as used herein, is a wound on the surface of the body that is exposed to the exterior of the body, such as an injury or damage to the epidermis, dermis, and / or subcutaneous layer. Surface wounds can include, for example, an ulcer or a closed incision. As used herein, a surface wound does not include wounds within the abdominal cavity. Wounds can include, for example, chronic, acute, traumatic, subacute, and dehiscence wounds, partial thickness burns, ulcers (such as diabetic ulcers, pressure ulcers, or venous insufficiency ulcers), skin flaps, and tissue grafts.
[0017] Treatment system 100 may include a negative pressure source or supply, such as negative pressure source 102, and one or more distribution components. The distribution components are preferably detachable and may be disposable, reusable, or recyclable. Dressings, such as dressing 104, and fluid containers, such as container 106, are examples of distribution components that may be associated with some embodiments of treatment system 100. As shown in the example of FIG. 1, dressing 104 may include or consist essentially of tissue interface 108, cover 110, or both in some embodiments.
[0018] A fluid conduit is another illustrative example of a distribution component. In this context, "fluid conduit" broadly includes a tube, pipe, hose, conduit, or other structure having one or more lumens or open passages adapted to transport fluid between two ends. Typically, a tube is an elongated, cylindrical structure with some flexibility, although the geometry and stiffness can vary. Additionally, some fluid conduits may be molded into or otherwise integrally combined with other components. Distribution components may also include or comprise interfaces or fluid ports to facilitate coupling and decoupling of other components. In some embodiments, for example, a dressing interface may facilitate coupling the fluid conduit to the dressing 104. For example, such a dressing interface may be a SENSAT.RAC™ Pad available from Kinetic Concepts, Inc. (San Antonio, Texas).
[0019] The treatment system 100 may also include a regulator or controller, such as a controller 112. Additionally, the treatment system 100 may include sensors for measuring operating parameters and providing feedback signals indicative of the operating parameters to the controller 112. For example, as shown in FIG. 1 , the treatment system 100 may include a first sensor 114 and a second sensor 116 coupled to the controller 112.
[0020] The treatment system 100 may also include a source of instillation solution. For example, the solution source 118 may be fluidly coupled to the dressing 104, as shown in the exemplary embodiment of FIG. 1 . The solution source 118 may be fluidly coupled to a positive pressure source, such as the positive pressure source 120, a negative pressure source, such as the negative pressure source 102, or both, in some embodiments. A regulator, such as the drip regulator 122, may also be fluidly coupled to the solution source 118 and the dressing 104 to ensure proper administration of the instillation solution (e.g., saline) to the tissue site. For example, the drip regulator 122 may include a piston that may be pneumatically actuated by the negative pressure source 102 to draw the instillation solution from the solution source during negative pressure intervals and to instill the solution onto the dressing during ventilation intervals. Additionally or alternatively, the controller 112 may be coupled to the negative pressure source 102, the positive pressure source 120, or both, to control the administration of the instillation solution to the tissue site. In some embodiments, the drip regulator 122 may be fluidly coupled to the negative pressure source 102 through the dressing 104.
[0021] Some components of the treatment system 100 may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy. For example, in some embodiments, the negative pressure source 102 may be combined with the controller 112, the solution source 118, and other components into a treatment unit.
[0022] In general, the components of the treatment system 100 may be directly or indirectly coupled. For example, the negative pressure source 102 may be directly coupled to the container 106 or indirectly coupled to the dressing 104 via the container 106. The coupling may include fluidic, mechanical, thermal, electrical, or chemical coupling (such as a chemical bond), or, in some contexts, some combination of couplings. For example, the negative pressure source 102 may be electrically coupled to the controller 112 and fluidly coupled to one or more distribution components to provide a fluid pathway to the tissue site. In some embodiments, components may also be coupled by physical proximity, by being integrated into a single structure, or by being formed from the same piece of material.
[0023] A negative pressure source, such as negative pressure source 102, may be a reservoir of air at negative pressure or may be a manual or powered device, such as a vacuum pump, a suction pump, a wall suction port available in many medical facilities, or a micropump. "Negative pressure" generally refers to a pressure less than the local ambient pressure, such as the ambient pressure in the local environment outside the sealed treatment environment. Often, the local ambient pressure may also be the atmospheric pressure where the tissue site is located. Alternatively, the pressure may be less than the hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise indicated, pressure values described herein are gauge pressures. References to increased negative pressure typically refer to decreases in absolute pressure, and decreases in negative pressure typically refer to increases in absolute pressure. While the amount and nature of the negative pressure provided by negative pressure source 102 may vary depending on treatment requirements, the pressure is typically a low vacuum, also commonly referred to as a rough vacuum, between -5 mmHg (-667 Pa) and -500 mmHg (-66.7 kPa). A typical therapeutic range is between -50 mmHg (-6.7 kPa) and -300 mmHg (-39.9 kPa).
[0024] Container 106 represents a container, canister, pouch, or other storage component that may be used to manage exudate and other fluids drawn from a tissue site. In many environments, a rigid container may be preferred or required for fluid collection, storage, and disposal. In other environments, fluids may be properly disposed of without being stored in a rigid container, and a reusable container may reduce waste and costs associated with negative pressure therapy. In some embodiments, container 106 may comprise a canister having a collection chamber, a first inlet fluidly coupled to the collection chamber, and a first outlet fluidly coupled to the collection chamber and adapted to receive negative pressure from a negative pressure source.
[0025] A controller, such as controller 112, may be a microprocessor or computer programmed to operate one or more components of treatment system 100, such as negative pressure source 102. In some embodiments, for example, controller 112 may be a microcontroller, which generally includes an integrated circuit including a processor core and memory programmed to directly or indirectly control one or more operating parameters of treatment system 100. The operating parameters may include, for example, the power applied to negative pressure source 102, the pressure generated by negative pressure source 102, or the pressure delivered to tissue interface 108. Controller 112 is also preferably configured to receive one or more input signals, such as feedback signals, and is programmed to modify one or more operating parameters based on the input signals.
[0026] Sensors, such as the first sensor 114 and the second sensor 116, are generally known in the art as any device operable to detect or measure a physical phenomenon or characteristic and generally provide a signal indicative of the detected or measured phenomenon or characteristic. For example, the first sensor 114 and the second sensor 116 may be configured to measure one or more operating parameters of the treatment system 100. In some embodiments, the first sensor 114 may be a transducer configured to measure the pressure in the air passageway and convert the measurement into a signal indicative of the measured pressure. In some embodiments, for example, the first sensor 114 may be a piezoresistive strain gauge. In some embodiments, the second sensor 116 may optionally measure an operating parameter of the negative pressure source 102, such as voltage or current. Preferably, the signals from the first sensor 114 and the second sensor 116 are suitable as input signals to the controller 112, although in some embodiments, some signal conditioning may be appropriate. For example, the signals may need to be filtered or amplified before they can be processed by the controller 112. Typically, the signal is an electrical signal, but may be represented in other forms, such as an optical signal.
[0027] The tissue interface 108 may generally be adapted to partially or completely contact the tissue site. The tissue interface 108 may take many forms and may have many sizes, shapes, or thicknesses, depending on various factors, such as the type of procedure being performed or the nature and size of the tissue site. The tissue interface 108 may further promote granulation at the tissue site when pressure within the sealed therapy environment is reduced. For example, the size and shape of the tissue interface 108 may be adapted to the contours of a deep, irregularly shaped tissue site. Some or all of the surface of the tissue interface 108 may have an uneven, rough, or jagged profile, which may induce microstrains and stresses at the tissue site when negative pressure is applied through the tissue interface 108.
[0028] In some embodiments, the tissue interface 108 may comprise or consist essentially of a manifold. A manifold in this context may comprise or consist essentially of a means for collecting or distributing fluid across the tissue interface 108 under pressure. For example, the manifold may be adapted to receive negative pressure from a source and distribute the negative pressure across the tissue interface 108 through a plurality of openings, which may have the effect of collecting fluid across the tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed, or a secondary fluid path may be provided to facilitate delivery of fluid across the tissue site, such as fluid from a source of dripping solution.
[0029] The tissue interface 108 can be either hydrophobic or hydrophilic. In instances where the tissue interface 108 may be hydrophilic, the tissue interface 108 can also wick fluid away from the tissue site while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 108 can draw fluid away from the tissue site by capillary flow or other wicking mechanisms. One example of a hydrophilic material that may be suitable is an open-cell foam of polyvinyl alcohol, such as VACWHITEFOAM™ dressing available from Kinetic Concepts, Inc. (San Antonio, Texas). Other hydrophilic foams may include those made from polyethers. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to impart hydrophilic properties.
[0030] In some embodiments, the tissue interface 108 may be constructed from a bioabsorbable material. Suitable bioabsorbable materials may include, but are not limited to, polymer blends of polylactic acid (PLA) and polyglycolic acid (PGA). Polymer blends may also include, but are not limited to, polycarbonate, polyfumarate, and caprolactone. The tissue interface 108 may further function as a scaffold for new cell growth, or a scaffold material may be used in conjunction with the tissue interface 108 to promote cell growth. A scaffold is generally a substance or structure used to enhance or promote cell growth or tissue formation, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA / PGA, coral hydroxyapatite, carbonate, or engineered allograft materials.
[0031] In some embodiments, the cover 110 can provide a barrier against bacteria and protection from physical trauma. The cover 110 can also be constructed from a material that can reduce evaporative loss and provide a fluid seal between two components or two environments, such as a fluid seal between a therapy environment and a local external environment. The cover 110 can include or consist of, for example, an elastomeric film or membrane that can provide a seal adequate to maintain the negative pressure of a given negative pressure source at the tissue site. In some applications, the cover 110 can have a high moisture-vapor transmission rate (MVTR). For example, in some embodiments, the MVTR can be at least 250 grams per square meter per 24 hours as measured using the Upright Cup Method of ASTM E96 / E96M at 38°C and 10% relative humidity (RH). In some embodiments, an MVTR of up to 5,000 grams per square meter per 24 hours can provide effective breathability and mechanical properties.
[0032] In some exemplary embodiments, the cover 110 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquids. Such drapes typically have a thickness in the range of 25 to 50 micrometers. For permeable materials, the permeability should generally be low enough to maintain the desired negative pressure. The cover 110 may include, for example, one or more of the following materials: polyurethanes (PU), such as hydrophilic polyurethanes; cellulose derivatives; hydrophilic polyamides; polyvinyl alcohol; polyvinylpyrrolidone; hydrophilic acrylics; silicones, such as hydrophilic silicone elastomers; natural rubber; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; ethylene vinyl acetate (EVA); copolyesters; and polyether block polyimide copolymers. Such materials are commercially available, for example, as Tegaderm® drapes available from 3M Company (Minneapolis, Minnesota); polyurethane (PU) drapes available from Avery Dennison Corporation (Pasadena, California), such as polyether block polyamide copolymer (PEBAX) from Arkema SA (Colombes, France); and Inspire 2301 and Inspire 2327 polyurethane films available from Expopack Advanced Coatings (Wrexham, United Kingdom). In some embodiments, the cover 110 has a thickness of 2600 g / m 2 / INSPIRE2301 having a 24 hour MVTR (upright cup method) and a thickness of approximately 30 micrometers.
[0033] An attachment device may be used to attach the cover 110 to a mounting surface, such as an intact epidermis, a gasket, or another cover. The attachment device may take many forms. For example, the attachment device may be a medically acceptable pressure-sensitive adhesive configured to bond the cover 110 to the epidermis around the tissue site. In some embodiments, for example, part or all of the cover 110 may be coated with an adhesive, such as an acrylic adhesive, which may have a coating weight of approximately 25-65 grams per square meter (gsm). In some embodiments, a thicker adhesive, or combination of adhesives, may be applied to improve the seal and reduce leakage. Other exemplary embodiments of the attachment device may include double-sided tape, glue, hydrocolloid, hydrogel, silicone gel, or organogel.
[0034] The solution source 118 may also represent a container, canister, pouch, bag, or other storage component capable of providing a solution for instillation therapy. While the composition of the solution may vary depending on the indicated therapy, examples of solutions that may be suitable for some formulations include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions.
[0035] In operation, the tissue interface 108 may be positioned within, on, over, or otherwise adjacent to the tissue site. For example, if the tissue site is a wound, the tissue interface 108 may partially or completely occlude or be positioned over the wound. The cover 110 may be positioned over the tissue interface 108 and sealed to a mounting surface adjacent the tissue site. For example, the cover 110 may be sealed to intact epidermis surrounding the tissue site. Thus, the dressing 104 can provide a sealed treatment environment adjacent the tissue site that is substantially isolated from the external environment, and the negative pressure source 102 can reduce pressure in that sealed treatment environment.
[0036] The fluid dynamics of using a negative pressure source to reduce pressure in another component or location, such as within a sealed treatment environment, can be mathematically complex, but the basic principles of fluid dynamics applicable to negative pressure therapy and instillation are generally well known to those skilled in the art, and the process of reducing pressure can be illustratively described herein as, for example, "delivering," "distributing," or "generating" negative pressure.
[0037] Generally, exudate and other fluids flow along a fluid pathway toward lower pressure. Thus, the term "downstream" typically refers to something in a fluid pathway that is relatively closer to a negative pressure source or farther away from a positive pressure source. Conversely, the term "upstream" refers to something that is relatively farther away from a negative pressure source or closer to a positive pressure source. Similarly, it may be convenient to describe certain features in terms of a fluid "inlet" or "outlet" in such a frame of reference. This orientation is generally assumed for purposes of describing various features and components herein. However, fluid pathways may also be reversed in some applications, such as by replacing a negative pressure source with a positive pressure source, and this descriptive definition should not be construed as limiting.
[0038] In a sealed treatment environment, negative pressure applied across the tissue site via tissue interface 108 can induce macro- and micro-strains at the tissue site. The negative pressure can also remove exudate and other fluids from the tissue site, which can be collected in container 106.
[0039] In some embodiments, the controller 112 can receive and process data from one or more sensors, such as the first sensor 114. The controller 112 can also control the operation of one or more components of the treatment system 100 to manage the pressure delivered to the tissue interface 108. In some embodiments, the controller 112 can include an input for receiving a desired target pressure and can be programmed to process data regarding the setting and input of the target pressure to be applied to the tissue interface 108. In some exemplary embodiments, the target pressure can be a fixed pressure value, which is set by an operator as the target negative pressure desired for therapy at the tissue site and then provided as an input to the controller 112. The target pressure may vary from tissue site to tissue site based on the type of tissue forming the tissue site, the type of injury or wound (if any), the patient's health, and the attending physician's preferences. After selecting the desired target pressure, the controller 112 can operate the negative pressure source 102 in one or more control modes based on the target pressure and can receive feedback from one or more sensors to maintain the target pressure at the tissue interface 108.
[0040] During tissue site treatment, some tissue sites may not heal according to normal medical protocols and may develop areas of necrotic tissue. Necrotic tissue can be dead tissue resulting from infection, poison, or trauma, which causes tissue to die faster than it can be removed by the body's normal processes regulating the removal of dead tissue. Sometimes, necrotic tissue can be in the form of slough, which can contain a viscous liquid mass of tissue. Slough is generally caused by bacterial and fungal infections that stimulate an inflammatory response in the tissue. Slough can be creamy yellow and sometimes referred to as pus. Necrotic tissue can also include scabs, which can be portions of necrotic tissue that have dried and hardened. Scabs can be the result of burns, gangrene, ulcers, fungal infections, spider bites, or anthrax. Removing scabs can be difficult without the use of surgical excision instruments.
[0041] For example, in addition to necrotic tissue, slough, and scab, a tissue site may contain biofilm, lacerated tissue, devitalized tissue, contaminated tissue, damaged tissue, infected tissue, exudate, thick exudate, fibrinous slough, and / or other material that may generally be referred to as debris. Debris may inhibit the effectiveness of tissue treatment and delay healing of the tissue site. If debris is present within the tissue site, the tissue site may be treated with various processes to destroy the debris. Examples of destruction may include softening the debris, separating the debris from desired tissue, such as subcutaneous tissue, preparing the debris for removal from the tissue site, and removing the debris from the tissue site.
[0042] The debris may require debridement, which may be performed in an operating room. In some cases, the tissue site requiring debridement may not be life-threatening, and debridement may be considered a low priority. Low-priority cases may experience delays before treatment as other, more life-threatening cases are given priority in the operating room. As a result, low-priority cases may require palliative care. Palliative care may include stasis of fluid flow at the tissue site to limit deterioration of the tissue site before other therapies, such as debridement, negative pressure therapy, or instillations.
[0043] During debridement, clinicians may find it difficult to distinguish between healthy, viable tissue and necrotic tissue. As a result, typical debridement techniques may remove too much healthy tissue or not enough necrotic tissue. When the nonviable tissue border does not extend deeper than the deep dermis layer, or when the tissue site is covered by debris such as slough or fibrin, gentle methods of debris removal should be considered to avoid excessive damage to the tissue site.
[0044] Some debridement processes use a mechanical process to remove debris. Mechanical processes may include the use of a scalpel or other cutting tool with a thin blade to cut debris from the tissue site. Other mechanical processes may use devices that provide a stream of particles that impact the debris to remove it in an abrasive process, or devices that provide a jet of high-pressure fluid that impacts the debris to remove it by water jet ablation or irrigation. Typically, the mechanical process of debridement of the tissue site can be painful and may require the application of a local anesthetic. Mechanical processes also carry the risk of removing excessive healthy tissue, which can cause further damage to the tissue site and delay the healing process. In some debridement processes, a dressing that may cover the tissue site is generally removed to allow access to the tissue site for debridement, preventing the use of the dressing for extended wear times. Thus, patients requiring debridement may not receive the protective and therapeutic benefits provided by wearing the dressing for a medically beneficial period.
[0045] Debridement can also be performed by an autolysis process. For example, an autolysis process can involve the use of enzymes and moisture produced by the tissue site to soften and liquefy necrotic tissue and debris. Typically, a dressing can be placed over the tissue site with debris so that fluids produced by the tissue site can remain in place and hydrate the debris. The autolysis process can be painless, but is slow and can take many days. Because the autolysis process is slow, it can also involve multiple dressing changes. Some autolysis processes can be paired with negative pressure therapy so that negative pressure supplied to the tissue site can pull the debris away as it is hydrated. In some cases, a manifold placed at the tissue site to distribute negative pressure across the tissue site can become blocked or clogged with debris decomposed by the autolysis process. If the manifold becomes clogged, the negative pressure may not be able to remove the debris, and the autolysis process may slow or stop. Additionally, granulation tissue ingrowth may be a concern if the manifold is left at the tissue site for an extended period of time, for example, to aid in healing of the tissue site as debris is removed.
[0046] Debridement can also be performed by adding enzymes or other agents to the tissue site that digest the tissue. Often, the placement of the enzyme and the length of time the enzyme is in contact with the tissue site must be kept strictly controlled. If the enzyme is left at the tissue site longer than necessary, the enzyme may remove too much healthy tissue, contaminate the tissue site, or be carried to other areas of the patient. If carried to other areas of the patient, the enzyme may degrade intact tissue and cause other complications.
[0047] These limitations and others may be addressed by therapy system 100, which can provide negative pressure therapy, drip therapy, and debris destruction. In some embodiments, therapy system 100 can provide mechanical movement at the surface of a tissue site in combination with the periodic delivery and dwell of a topical solution that aids in the solubilization of debris. For example, a negative pressure source may be fluidly coupled to the tissue site to provide negative pressure to the tissue site for negative pressure therapy. In some embodiments, a fluid source may be fluidly coupled to the tissue site to provide therapeutic fluid to the tissue site for drip therapy. In some embodiments, therapy system 100 may include a contact layer disposed adjacent to the tissue site that can be used by negative pressure therapy, drip therapy, or both to destroy regions of the tissue site having debris. Following debris destruction, negative pressure therapy, drip therapy, and other processes may be used to remove the debris from the tissue site. In some embodiments, therapy system 100 may be used in conjunction with other tissue removal and debridement techniques. For example, therapy system 100 may be used prior to enzymatic debridement to soften debris. In another example, mechanical debridement may be used to remove a portion of the debris at a tissue site, and then therapy system 100 may be used to remove the remaining debris while reducing the risk of trauma to the tissue site. Therapy system 100 may also provide a dressing that can be worn for extended periods of time and provide tissue debridement while preventing granulation tissue ingrowth. Extended-wear dressings can provide cost savings, time efficiency, and reduced trauma to the patient during dressing changes.
[0048] FIG. 2 is an assembled view of one example of the dressing 104 of FIG. 1 , illustrating additional details that may be relevant to some embodiments. The dressing 104 may include a tissue interface 108 and a cover 110. In some embodiments, the tissue interface 108 may include a manifold or debridement tool, such as a first layer 202, and a contact layer, such as a second layer 204. The first layer may include a first side 206 and a second side 208 opposite the first side 206. The first layer 202 may have a substantially uniform thickness 220 extending from the first side 206 to the second side 208. In some embodiments, the thickness 220 of the first layer 2020 may be between about 2 millimeters and about 12 millimeters. In other embodiments, the thickness 220 of the first layer 202 may be selected for a particular application of the tissue interface 108. The second layer 204 may also be flexible so that the second layer 204 may conform to the contours of the surface of the tissue site.
[0049] In some embodiments, the first layer 202 may comprise a foam. For example, the first layer 202 may include a reticulated foam having a pore size and free volume that can be varied depending on the needs of the indicated therapy. For example, a reticulated foam having a free volume of at least 90% may be suitable for many therapeutic applications, while a foam having an average pore size in the range of 400-600 micrometers may be particularly suitable for some types of therapy. The tensile strength of the first layer 202 may also be varied depending on the needs of the indicated therapy. For example, the tensile strength of the foam may be increased due to the instillation of a topical treatment solution. The 25% compressive load deflection of the first layer 202 may be at least 2.2 pounds per square inch. In some embodiments, the tensile strength of the first layer 202 may be at least 18 pounds per square inch. The first layer 202 may have a tear strength of at least 4 pounds per inch. In some embodiments, first layer 202 may be a foam composed of a polyol, such as a polyester or polyether, an isocyanate, such as toluene diisocyanate, and a polymerization modifier, such as an amine or a tin compound. In some examples, first layer 202 may be a reticulated polyurethane foam such as that used in GRANUFOAM™ dressings or VACVERAFLO™ dressings, both available from KCI (San Antonio, Texas).
[0050] In some embodiments, the first layer 202 may be formed from a foam that is mechanically or chemically compressed, often as part of a thermoforming process, to increase the foam's density at ambient pressure. Mechanically or chemically compressed foam may be referred to as compressed or felted foam. In some embodiments, the first layer 202 may be formed from a felting process. Felting involves a thermoforming process that permanently compresses foam to increase the foam's density while maintaining interconnected pathways. For example, felting may be performed by applying heat and pressure to a porous or foam material. Some methods may include compressing a foam blank between one or more heated platens or dies (not shown) at a specific temperature for a specific period of time. The direction of compression may be along the thickness of the foam blank.
[0051] The period of compression may range from 10 minutes to 24 hours, but may be longer or shorter depending on the particular type of porous material used. Additionally, in some instances, the temperature may range between 120°C and 260°C. Generally, the lower the platen temperature, the longer the porous material must be held in a compressed state. After a specific period of time, the pressure and heat are passed over or through the porous material or portion of the porous material to form a felt structure or surface.
[0052] The felting process may change certain properties of the original material, including pore shape and / or size, elasticity, density, and density distribution. For example, struts defining pores in a foam may be deformed during the felting process, resulting in a flattened pore shape. The deformed struts may also reduce the elasticity of the foam. The density of a foam generally increases with felting. In some embodiments, contact with the hot press platen during the felting process may also result in a density gradient, where the density is higher at the surface and the pore size is smaller or eliminated at the surface. For example, at least a portion of the first layer 202 may be felted to the point where it is pore-free. In some embodiments, the felt structure may be relatively smoother than any unfinished or unfelted surface or portion of the porous material. Furthermore, the pores within the felt structure may be smaller than the pores throughout any unfinished or unfelted surface or portion of the porous material. In some examples, the felt structure may be applied to all surfaces or portions of the porous material. Additionally, in some instances, the felt structure may extend through the entire thickness of the porous material such that the entire porous material is felted.
[0053] Felt foam can be characterized by a hardness factor, which indicates the compression of the foam. The hardness factor of a felt foam can be specified as the ratio of its original thickness to its final thickness. Compressed or felted foams can have a hardness factor greater than 1. The degree of compression can affect the physical properties of the felt foam. For example, felt foams have a higher effective density than unfelted foams of the same material. The felting process can also affect the interaction of the fluid with the foam. For example, as density increases, compressibility or crushability can decrease. Thus, foams with different compressibility or crushability can have different hardness factors. In some exemplary embodiments, the hardness factor can range from about 2 to about 10, and preferably from about 3 to about 5. For example, the hardness factor of the felt foam of the first layer 202 can be about 5 in some embodiments. There is a general linear relationship between hardness level, density, pore size (or pores per inch), and compressibility. For example, foam felted to a hardness factor of 3 exhibits a three-fold density increase and is compressed to approximately one-third of its original thickness.
[0054] In some embodiments, one or more suitable foam blanks (e.g., pre-felted foam) may be used to form the first layer 202. The foam blank(s) may have an average of about 40 to about 150 holes per inch, about 5.1 to about 6.3 lb / ft 3The foam blank(s) may have a density of at least 2.2 pounds per square inch, an average pore size in the range of about 133 to about 600 micrometers, a 25% compression load deflection of at least 2.2 pounds per square inch, and / or a 65% compression load deflection of at least 2.2 pounds per square inch. In some embodiments, the foam blank(s) may have a thickness greater than 10 millimeters. For example, the foam blank(s) may have a thickness in the range of about 10 to about 35 millimeters, about 10 to about 25 millimeters, about 10 to about 20 millimeters, or about 15 to about 20 millimeters. In some embodiments, the foam blank(s) may be felted to provide a higher density foam for first layer 202. For example, one or more foam blanks may be felted to a hardness factor of 2 to 10 to form first layer 202. In some embodiments, the foam blanks may be felted to a hardness factor of 3 to 7. Some embodiments may felt the foam blanks to a hardness factor of 5.
[0055] In some embodiments, the first layer 202 has a free volume in the range of about 9% to about 45%, about 2.6 to about 16 lb / ft 3 In some embodiments, the first layer 202 may be an open-cell foam having a density in the range of about 18% to about 45%, an average of about 80 to about 500 pores per inch when measured in the compression direction, an average pore size in the range of about 40 to about 300 micrometers when measured in the compression direction, and / or a 25% compression load deflection of about 0.7 to about 3.5 pounds per square inch and a 65% compression load deflection of about 0.86 to about 4.3 pounds per square inch, which may be particularly advantageous under negative pressure. In some embodiments, the first layer 202 has a free volume in the range of about 18% to about 45%, a free volume of about 2.6 to about 8 lb / ft 3 in the range of 0.1 to 0.5 mm, an average of about 40 to about 250 pores per inch (e.g., as measured in the direction of compression), an average pore size (e.g., as measured in the direction of compression) in the range of about 80 to about 600 micrometers, and / or a 25% compression load deflection of about 2.2 pounds per square inch and a 65% compression load deflection of about 2.2 pounds per square inch, which may be particularly advantageous under negative pressure.
[0056] As further shown in FIG. 2 , the first layer 202 may include a plurality of through-holes 210 extending through the first layer 202 from the first side 206 to the second side 208. The plurality of through-holes 210 may be uniformly or randomly distributed throughout the first layer 202. The plurality of through-holes 210 extending through the first layer 202 may form walls 212 extending through the first layer 202. The through-holes 210 may have a depth approximately equal to the thickness 220 of the first layer 202. For example, the through-holes 210 may have a depth of about 2 millimeters to about 12 millimeters. In some embodiments, the through-holes 210 may have a depth of about 8 millimeters.
[0057] In some embodiments, at least one of the plurality of through holes 210 may be located at an edge of the first layer 202. For example, at least one of the plurality of through holes 210 may be located at the periphery 222 of the first layer 202, with an inner portion of the through hole 210 exposed. In some embodiments, the plurality of through holes 210 located at or near the periphery 222 of the first layer 202 may be substantially equally spaced around the periphery 222. Additionally or alternatively, the spacing of the plurality of through holes 210 proximate the periphery 222 of the first layer 202 may be irregular.
[0058] In some embodiments, the second layer 204 may be configured to be disposed adjacent to the second side 208 of the first layer 202. For example, the second layer 204 and the first layer 202 may be overlapped such that the second layer 204 contacts the first layer 202. In some embodiments, the second layer 204 may be bonded to the second side 208 of the first layer 202.
[0059] The second layer 204 may include a means for controlling or managing fluid flow. In some embodiments, the second layer 204 may be a fluid control layer including a liquid-impermeable elastomeric material. For example, the second layer 204 may be a polymer film, such as a polyurethane film. In some embodiments, the second layer 204 may be the same material as the cover 110. The second layer 204 may also have a smooth or matte surface texture. A polished or glossy finish, such as grade B3 or higher according to the Society of Plastics Industry (SPI) standard, may be particularly advantageous for some applications. In some embodiments, the variation in surface height may be limited to an acceptable tolerance. For example, the surface of the second layer 204 may have a substantially flat surface and the variation in height may be limited to 0.2 millimeters over 1 centimeter.
[0060] In some embodiments, the second layer 204 may be hydrophobic. The hydrophobicity of the second layer 204 may vary, but in some embodiments, the second layer 204 may have a contact angle with water of at least 90 degrees. In some embodiments, the second layer 204 may have a contact angle with water of 150 degrees or less. For example, in some embodiments, the contact angle of the second layer 204 may be in the range of at least 90 degrees to about 120 degrees, or in the range of at least 120 degrees to 150 degrees. Water contact angles may be measured using any standard device. While a manual goniometer may be used to visually estimate the contact angle, contact angle measurement devices often include an integrated system with, among other things, a horizontal stage, a liquid dropper such as a syringe, a camera, and software designed to more accurately and precisely calculate the contact angle. Non-limiting examples of such integrated systems include the FTA125, FTA200, FTA2000, and FTA4000 systems, all commercially available from First Ten Angstroms, Inc. (Portsmouth, VA), and the DTA25, DTA30, and DTA100 systems, all commercially available from Kruss GmbH (Hamburg, Germany). Unless otherwise specified, water contact angles herein are measured using deionized distilled water on a horizontal sample surface, with a drop applied from a height of 5 cm or less, in air at 20-25°C and 20-50% relative humidity. Contact angles herein represent the average of 5-9 measurements, discarding both the highest and lowest measurements. The hydrophobicity of the second layer 204 may be further enhanced by hydrophobic coatings of other materials, such as silicones or fluorocarbons, during either liquid or plasma coating.
[0061] The second layer 204 may also be suitable for welding to other layers, including the first layer 202. For example, the second layer 204 may be adapted for welding to polyurethane foam using heat, radio frequency (RF) welding, or other methods that generate heat, such as ultrasonic welding. RF welding may be particularly suitable for more polar materials, such as polyurethane, polyamide, polyester, and acrylate. A sacrificial polarity interface may be used to facilitate RF welding of less polar film materials, such as polyethylene. In some embodiments, the second layer 204 may be flame laminated to the first layer 202.
[0062] The areal density of the second layer 204 may vary depending on the prescribed therapy or application. In some embodiments, an areal density of less than 40 grams per square meter may be suitable, and an areal density of about 20-30 grams per square meter may be particularly advantageous for some applications.
[0063] In some embodiments, for example, the second layer 204 may be a hydrophobic polymer such as a polyethylene film. The simple and inert structure of polyethylene can provide a surface that interacts little, if at all, with biological tissue and fluids, promoting free flow and low adhesion of liquids, which may be particularly advantageous for many applications. Other suitable polymer films include polyurethane, acrylic, polyolefin (such as cyclic olefin copolymer), polyacetate, polyamide, polyester, copolyester, PEBAX block copolymer, thermoplastic elastomer, thermoplastic vulcanizate, polyether, polyvinyl alcohol, polypropylene, polymethylpentene, polycarbonate, styrenes, silicone, fluoropolymer, and acetate. Thicknesses between 20 micrometers and 100 micrometers may be suitable for many applications. The film may be clear, colored, or printed. More polar films suitable for laminating to polyethylene film include polyamide, copolyester, ionomer, and acrylic. Tie layers such as ethylene vinyl acetate or modified polyurethane may be used to aid in bonding between the polyethylene and the polar film. Ethyl methyl acrylate (EMA) film may also have hydrophobic and welding properties that make it suitable for some configurations.
[0064] The second layer 204 may have a set of one or more fluid passages, which may be uniformly or randomly distributed throughout the second layer 204. In some embodiments, the passages may be bidirectional and pressure-responsive. For example, each of the passages may be a resilient passage that is generally not normally taut to substantially reduce the flow of liquid, but may expand or open in response to a pressure gradient and / or in response to contraction of the first layer 202. In some embodiments, multiple fluid restriction portions 214 may be disposed in the second layer 204. The multiple fluid restriction portions 214 may be formed by removing material from the second layer 204. For example, the multiple fluid restriction portions 214 may be formed by cutting through the second layer 204. When no pressure gradient exists across the multiple fluid restriction portions 214, the multiple fluid restriction portions 214 may be small enough to form a seal that can substantially reduce or prevent the flow of liquid. Additionally or alternatively, one or more of the passageways may be or function as elastomeric valves that are normally closed when not tensioned to substantially prevent liquid flow and that may open in response to a pressure gradient and / or in response to contraction of the first layer 202. In some embodiments, the plurality of fluid restriction portions 214 may be fenestrations in the second layer 204. In some embodiments, at least a portion of the plurality of fluid restriction portions 214 may be aligned with at least a portion of the plurality of through-holes 210 in the first layer 202.
[0065] In some embodiments, a plurality of perforations 216 may also be disposed in the second layer 204. The plurality of perforations 216 may be formed, for example, by cutting, by application of localized radio frequency (RF) or ultrasonic energy, or by other suitable techniques for forming openings. The plurality of perforations 216 in the second layer 204 may be configured to align with the plurality of through-holes 210 in the first layer 202. In other embodiments, the plurality of perforations 216 may have a uniform distribution pattern or may be randomly distributed on the second layer 204. The plurality of perforations 216 may also have many shapes, including circular, square, oval, polygonal, and irregular.
[0066] At least one of the plurality of perforations 216 may be located at an edge of the second layer 204. For example, at least one of the plurality of perforations 216 may be located at a peripheral edge 218 of the second layer 204, and an inner portion of the perforation 216 may be exposed. The plurality of perforations 216 located at or near the peripheral edge 218 of the second layer 204 may be substantially equally spaced around the peripheral edge 218. Additionally or alternatively, the spacing of the plurality of perforations 216 proximate the peripheral edge 218 of the second layer 204 may be irregular.
[0067] In some embodiments, the dressing 104 may include a fluid conduit 224 and a dressing interface 226. In some embodiments, the fluid conduit 224 may be a flexible tube. In some embodiments, the fluid conduit may comprise a first end 230 and a second end 232. The first end 230 of the fluid conduit 224 may be configured to be fluidly coupled to the dressing interface 226, and the second end 232 of the fluid conduit 224 may be configured to be fluidly coupled to the negative pressure source 102 (not shown).
[0068] In some embodiments, the dressing interface 226 may be an elbow-type connector that may be positioned over an opening 228 in the cover 110 to provide a fluid pathway between the fluid conduit 224 and the tissue interface 108, as shown in the example of FIG. 2 . In other embodiments, the first end 230 of the fluid conduit 224 may be inserted directly through the cover 110 and into the tissue interface 108. The cover 110 may be configured to create a sealed space containing the first layer 202 and the second layer 204 at the tissue site 806. In some embodiments, the cover 110 may include an opening 228. In other embodiments, the opening 228 may be cut into the cover 110 before or after placing the cover 110 over the tissue interface 108. In some embodiments, the opening 228 may be centrally located in the cover 110. In other embodiments, the location of the opening 228 may be off-center or adjacent an end or edge of the cover 110.
[0069] In some embodiments, the tissue interface 108 may be provided as part of an assembly that forms the dressing 104. In other embodiments, the tissue interface 108 may be provided separately from the cover 110, the fluid conduits 224, and the dressing interface 226 for assembling the dressing 104 during use.
[0070] If not already configured, the dressing interface 226 may be placed over the opening 228 and attached to the cover 110. A first end 230 of the fluid conduit 224 may be fluidly coupled to the dressing interface 226, and a second end 232 of the fluid conduit 224 may be fluidly coupled to the negative pressure source 102.
[0071] 3 is a plan view of the first layer 202 of FIG. 2 showing additional details that may be relevant to some embodiments. The first layer 202 may include a plurality of through-holes 210 extending through the first layer 202 to form walls 212. In some embodiments, the through-holes 210 may have a circular shape. In other embodiments, the through-holes 210 may have other shapes and orientations, such as oval, hexagonal, square, triangular, polygonal, or irregular or irregular shapes.
[0072] In some embodiments, the inner surfaces of the walls 212 may be parallel to the thickness 220 of the first layer 202. In other embodiments, the inner surfaces of the walls 212 may be generally perpendicular to the first side 206 and the second side 208 of the first layer 202. The inner surfaces or surfaces of the walls 212 may form the perimeter 302 of each through-hole 210 and connect the first side 206 to the second side 208. In other embodiments, the through-holes 210 may be formed such that the inner surfaces of the walls 212 of the through-hole 210 form an angle other than perpendicular with the first side 206. In still other embodiments, the inner surfaces of the walls 212 of the through-hole 210 may taper toward the center 312 of the through-hole 210, forming a cone, pyramid, or other irregular through-hole shape. When the inner surfaces of the walls 212 of the through-hole 210 are tapered, the through-hole 210 may have a height that is less than the thickness 220 of the first layer 202.
[0073] In some embodiments, the first layer 202 can have a first orientation line 304 and a second orientation line 306 that is perpendicular to the first orientation line 304. The first orientation line 304 and the second orientation line 306 can be lines of symmetry for the first layer 202. The line of symmetry can be, for example, an imaginary line that intersects the first side 206 or the second side 208 of the first layer 202 and defines a fold line such that when the first layer 202 is folded at the line of symmetry, the through-holes 210 and the walls 212 are simultaneously aligned on each side. Although the first layer 202 is shown as being generally oval-shaped, including a longitudinal edge 308 and a circular edge 310, the first layer 202 can have other shapes. For example, the first layer 202 can have a rectangular, diamond, square, circular, triangular, or irregular shape. In some embodiments, the shape of the first layer 202 can be selected to accommodate the type of tissue site being treated. For example, the first layer 202 can have a circular shape to accommodate a circular tissue site. The first layer 202 can also be of a substantial size. For example, the first layer 202 can be cut, torn, or otherwise separated into portions to allow the first layer 202 to be reduced in size for smaller tissue sites. In some embodiments, the first orientation line 304 can be parallel to the longitudinal edge 308.
[0074] FIG. 4 is a detailed view of a portion of the first layer 202 of FIG. 3 , showing additional details that may be relevant to some embodiments. The first layer 202 may include a plurality of through-holes 210 aligned in parallel rows to form an array. The array of through-holes 210 may include a first row 402 of through-holes 210, a second row 404 of through-holes 210, and a third row 406 of through-holes 210. In some embodiments, the width 418 of the wall 212 between the peripheries 302 of consecutively adjacent through-holes 210, such as the first row 402, may be between about 2 millimeters and about 15 millimeters. In some embodiments, a width of about 5 millimeters may be preferred.
[0075] In some embodiments, a line connecting the centers 312 of adjacent rows may form a strut angle (SA) with the first orientation line 304. For example, a first through-hole 210A in the first row 402 may have a center 312A, and a second through-hole 210B in the second row 404 may have a center 312B. A strut line 412 may connect the centers 312A and 312B. The strut line 412 may form an angle 414 with the first orientation line 304. The angle 414 may be the strut angle (SA) of the first layer 202. In some embodiments, the strut angle (SA) may be less than about 90°. In other embodiments, the strut angle (SA) may be between about 30° and about 70° relative to the first orientation line 304. In other embodiments, the strut angle (SA) may be about 66° from the first orientation line 304. Generally, as the strut angle (SA) decreases, the stiffness of the first layer 202 in a direction parallel to the first orientation line 304 may increase.
[0076] In some embodiments, the centers 312 of through-holes 210 in alternating rows, e.g., center 312A of first through-hole 210A in first row 402 and center 312C of through-hole 210C in third row 406, can be spaced apart from one another parallel to second azimuth line 306 by length 416. In some embodiments, length 416 can be greater than the effective diameter of through-hole 210. In some embodiments, length 416 can be between about 2 mm and about 10 mm. When centers 312 of through-holes 210 in alternating rows are separated only by length 416, the outer surface of wall 212 parallel to first azimuth line 304 can be considered continuous. In general, the outer surface of wall 212 can be continuous if the outer surface of wall 212 does not have discontinuities or breaks between through-holes 210.
[0077] In some embodiments, the through-holes 210 may be formed during molding of the first layer 202. In other embodiments, the through-holes 210 may be formed by cutting, melting, drilling, or vaporizing the first layer 202 after the first layer 202 is formed. For example, the through-holes 210 may be formed in the first layer 202 by laser ablating the compressed foam of the first layer 202.
[0078] In some embodiments, the effective diameter of through-holes 210 can be selected to allow the flow of particulate matter through through-holes 210. In some embodiments, through-holes 210 can have an average effective diameter of about 5 millimeters to about 20 millimeters. In some embodiments, a diameter of about 10 millimeters is preferred.
[0079] In some embodiments, the diameter of the through-holes 210 can be selected based on the size of the solubilized debris to be lifted from the tissue site. Larger through-holes 210 can allow larger debris to pass through the first layer 202, while smaller through-holes 210 can allow smaller debris to pass through the first layer 202 while blocking debris larger than the through-holes 210. In some embodiments, successive applications of the dressing 104 can use first layers 202 with successively smaller diameters of through-holes 210 as the size of the solubilized debris at the tissue site decreases. Successively smaller diameters of the through-holes 210 can also help fine-tune the level of tissue disruption to the debris during treatment of the tissue site. The diameter of the through-holes 210 can also affect the movement of fluid within the first layer 202 and the dressing 104. For example, the first layer 202 can direct fluid within the dressing 104 toward the through-holes 210 to aid in the disruption of debris on the tissue site. Varying the diameter of the through-holes 210 can vary the manner in which fluid moves through the dressing 104, both with respect to fluid removal and application of negative pressure.
[0080] In other embodiments, the inner surfaces of the walls 212 of the plurality of through-holes 210 may be manufactured to prevent or reduce tissue granulation and tissue ingrowth. For example, the plurality of through-holes 210 may be formed by thermoforming the first layer 202, resulting in a smooth inner surface of the walls 212. As used herein, smoothness may refer to the formation of the through-holes 210 resulting in the inner surface of the walls 212 extending between the first side 206 and the second side 208. For example, laser ablating the through-holes 210 in the first layer 202 may plastically deform the material of the first layer 202 and close the holes in the inner surface of the walls 212 extending between the first side 206 and the second side 208. In some embodiments, the smooth inner surface of the walls 212 may limit or inhibit tissue ingrowth through the through-holes 210 into the first layer 202. In other embodiments, the smooth inner surface of wall 212 may be formed by a smooth material or a smooth coating applied to the inner surface of wall 212. In such embodiments, the plurality of perforations 216 in second layer 204 may have a diameter substantially equal to the diameter of the plurality of through-holes 210 to allow slough and other fluids to be removed from the tissue site through the perforations 216 and through-holes 210.
[0081] FIG. 5 is a plan view of the second layer 204 of FIG. 2 , showing additional details that may be relevant to some embodiments. A plurality of fluid restriction portions 214 may be formed as slits or slots in the second layer 204. In some embodiments, the plurality of fluid restriction portions 214 may be uniformly distributed across the second layer 204. For example, the fluid restriction portions 214 may be substantially coextensive with the second layer 204 and distributed across the second layer 204 in a grid of parallel rows and columns, with the slots also parallel to one another. Adjacent columns of fluid restriction portions 214 may be spaced apart by a distance D1, and the fluid restriction portions 214 within each column may be spaced apart by a distance D2. For example, a center-to-center distance D1 of approximately 3 millimeters and a center-to-center distance D2 of approximately 3 millimeters may be suitable for some embodiments. The fluid restriction portions 214 in adjacent columns may be aligned or offset. For example, adjacent rows of fluid restriction portions 214 may be offset as shown in FIG. 5, such that the fluid restriction portions 214 are aligned in alternating rows separated by a distance D3. In some examples, a distance D3 of about 6 millimeters may be suitable. In some embodiments, the spacing of the fluid restriction portions 214 may be varied to increase the density of the fluid restriction portions 214 according to treatment requirements.
[0082] Each of the plurality of perforations 216 disposed in the second layer 204 may have uniform or similar geometric characteristics. For example, in some embodiments, each of the plurality of perforations 216 may be circular and have substantially the same diameter. In some embodiments, each of the plurality of perforations 216 may have an effective diameter that is smaller than the effective diameter of each of the plurality of through-holes 210.
[0083] Although the second layer 204 is shown as having a generally oval shape, the second layer 204 may have other shapes. For example, the second layer 204 may have a rectangular, diamond, square, circular, triangular, or irregular shape. In some embodiments, the shape of the second layer 204 may be selected to accommodate the type of tissue site being treated. For example, the second layer 204 may have a circular shape to accommodate a circular tissue site. The second layer 204 may be sizable. For example, the second layer 204 may be cut, torn, or otherwise separated into portions to allow the second layer 204 to be reduced in size for smaller tissue sites. In some embodiments, the second layer 204 may be sized and shaped to substantially correspond to the size and shape of the first layer 202.
[0084] 6 is a detailed view of a portion of the second layer 204 of FIG. 5, showing additional details that may be relevant to some embodiments. The plurality of fluid restriction portions 214 may be formed as slits or slots in the second layer 204. Each of the plurality of fluid restriction portions 214 has a length L P and width W P and may consist essentially of one or more linear slots having a length L P extends parallel to the second azimuth line 306 and has a width W P extends parallel to the first azimuth line 304. In some embodiments, the plurality of fluid restriction portions 214 have a length L of less than 6 millimeters. P and width W less than 2 mm P In some embodiments, the slot may be a linear slot having a length L P may be at least 3 mm, and the width W P may be at least 0.5 mm. P and a width W of approximately 1 mm P However, this may be particularly suitable for many applications, where a tolerance of about 0.1 millimeters may be acceptable. Pmay be selected for a particular application, and tolerances of about 0.1 millimeters may also be acceptable. Such dimensions and tolerances may be achieved, for example, with a laser cutter. Slots of this configuration may function as imperfect elastomeric valves that can substantially reduce liquid flow in a normally closed or quiescent state. For example, such slots may form flow restrictions without completely closing or sealing. In response to a pressure gradient and / or contraction of the first layer 202, the slots may expand or open wider, allowing for increased liquid flow.
[0085] FIG. 7 is a detailed view of a portion of the second layer 204 of FIG. 5 , showing additional details that may be relevant to some embodiments. The second layer 204 may include a plurality of perforations 216 aligned in parallel rows to form an array. The array of perforations 216 may include a first row 702 of perforations 216, a second row 704 of perforations 216, and a third row 706 of perforations 216. Each of the plurality of perforations 216 may have a center 708. The centers 708 of perforations 216 in adjacent rows, e.g., the first row 702 and the second row 704, may be characterized by being offset from the second orientation line 306 along the first orientation line 304. In some embodiments, the centers 708 of perforations 216 in adjacent rows may be spaced apart by between about 2 millimeters and about 6 millimeters. In some embodiments, the center 708 of the perforation 216 in the second layer 204 may be configured to align with the center 312 of the plurality of through-holes 210 in the first layer 202. For example, the center 708 of the perforation 216 may coincide with the center 312 of each of the plurality of through-holes 210.
[0086] In some embodiments, a line connecting the centers 708 of adjacent rows of perforations 216 may form a strut angle (SA) with the first orientation line 304. For example, a first perforation 216A in the first row 702 may have a center 708A, and a second perforation 216B in the second row 704 may have a center 708B. A strut line 710 may connect the centers 708A and 708B. The strut line 710 may form an angle 712 with the first orientation line 304. The angle 712 may be the strut angle (SA) of the second layer 204. In some embodiments, the strut angle (SA) may be less than about 90°. In other embodiments, the strut angle (SA) may be between about 30° and about 70° relative to the first orientation line 304. In other embodiments, the strut angle (SA) may be about 66° from the first orientation line 304.
[0087] In some embodiments, centers 708 of perforations 216 in alternating rows, e.g., center 708A of first perforation 216A in first row 702 and center 708C of third perforation 216C in third row 706, may be spaced apart from one another parallel to second azimuth line 306 by length 714. In some embodiments, length 714 may be between about 4 mm and about 6 mm. In some embodiments, length 714 may be greater than the effective diameter of perforations 216.
[0088] 8 is a cross-sectional view of the assembled tissue interface 108 of FIG. 2 taken along line 8-8, showing additional details that may be relevant to some embodiments. The tissue interface 108 may include a first layer 202 and a second layer 204. In some embodiments, the second layer 204 may have a first side 802 configured to be coupled to the second side 208 of the first layer 202. For example, the first side 802 of the second layer 204 may be bonded, glued, welded, or otherwise secured to the second side 208 of the first layer 202. In some embodiments, the second layer 204 may have a second side 804 opposite the first side 802 configured to be placed in direct contact with a tissue site 806.
[0089] The plurality of through holes 210 may extend through the thickness 220 of the first layer 202 from the first side 206 to the second side 208. In some embodiments, the wall 212 may be parallel to the thickness 220 of the first layer 202. The plurality of perforations 216 may extend through the second layer 204 from the first side 802 to the second side 804 and may have a periphery 808. In some embodiments, the center of each of the plurality of perforations 216 may be aligned with the center of each of the plurality of through holes 210. Additionally, the diameter of each of the plurality of perforations 216 may be smaller than the diameter of each of the through holes 210. In some embodiments, the periphery 808 of each of the plurality of perforations 216 may be configured to extend into each of the through holes 210 and cover at least a portion of the wall 212 under application of negative pressure, as described in more detail below.
[0090] FIG. 9 is a cross-sectional view of the assembled tissue interface of FIG. 2 taken along line 8-8 during negative pressure therapy, showing additional details that may be relevant to some embodiments. A cover 110 may be placed over the first layer 202 and the second layer 204 to create a sealed environment. FIG. 9 may show a point at which the pressure within the sealed environment may be negative, at approximately −125 mmHg. The negative pressure may create a pressure gradient across the second layer 204 that concentrates stress at the tissue site 806 adjacent the through-holes 210 in the first layer 202. This concentrated stress may cause at least a periphery 808 of each of the plurality of perforations 216 in the second layer 204 to extend into each of the plurality of through-holes 210 in the first layer 202. In some embodiments, the periphery of each of the plurality of perforations 216 may be configured to completely cover the wall 212 to form a port. In other embodiments, the periphery of each of the plurality of perforations 216 may be configured to cover at least a portion of the wall 212. In some embodiments, the concentrated stress may draw a portion of the subcutaneous tissue 902 at the tissue site 806 into the through-hole 210.
[0091] FIG. 10 is a detailed view of a portion of the tissue interface 108 of FIG. 9 , showing additional details of the tissue interface 108 during operation of negative pressure therapy. Generally, pressure within a sealed environment can exert a force proportional to the area over which the pressure is applied. In some embodiments, the force may be concentrated at the through-hole 210 in the first layer 202 and the plurality of perforations 216 in the second layer 204 because the resistance to application of negative pressure at the through-hole 210 and the plurality of perforations 216 is less than the resistance at the wall 212. In response to the force generated by the pressure at the through-hole 210 and the plurality of perforations 216, the periphery 808 of each of the plurality of perforations 216 can be drawn into and through the respective through-hole 210. The periphery 808 of each of the plurality of perforations 216 can cover at least a portion of the inner surface of the wall 212 of the through-hole 210, creating a port. In some embodiments, the periphery 808 of each of the plurality of perforations 216 can completely cover the inner surface of the wall 212 of the through-hole 210, creating a port. The port may allow thick slough and wound exudate to pass into and / or through the first layer 202. In some embodiments, at least a portion of the subcutaneous tissue 902 may be drawn into the through-hole 210. Additionally, the plurality of fluid restriction portions 214 in the second layer 204 may allow fluid, such as wound exudate, to be removed from the tissue site 806, through the plurality of fluid restriction portions 214, and into the first layer 202 under application of negative pressure.
[0092] The height of the walls 212, the diameter of the through-holes 210, and the diameter of the perforations 216 may be selected to ensure that the periphery 808 of the plurality of perforations 216 in the second layer 204 can completely cover the walls 212 of the through-holes 210 to inhibit tissue granulation and tissue ingrowth. In some embodiments, the second layer 204 may be configured to extend, and the diameter of the plurality of perforations 216 may be selected to ensure that the periphery 808 of each of the plurality of perforations 216 can extend into the through-hole 210 to cover the walls 212.
[0093] 11 is a perspective view of another example of the second layer 204 of FIG. 2 , showing additional details that may be relevant to some embodiments. In some embodiments, the second layer 204 may include a plurality of fluid restrictors 214 and a plurality of protrusions 1102. The plurality of protrusions 1102 may extend from the first side 802 of the second layer 204. In some embodiments, the plurality of protrusions 1102 may be thermoformed to create a cylindrical shape. In other embodiments, the plurality of protrusions 1102 may have other shapes and orientations, such as oval, hexagonal, square, triangular, polygonal, or irregular or irregular shapes.
[0094] In some embodiments, each of the plurality of protrusions 1102 may correspond to one of the plurality of through-holes 210. For example, each of the plurality of protrusions 1102 of the second layer 204 may be configured to extend into at least a portion of one of the plurality of through-holes 210 of the first layer 202. In other embodiments, there may be more through-holes 210 in the first layer 202 than protrusions 1102 in the second layer 204. For example, the plurality of protrusions 1102 may extend into one set of through-holes 210, and another set of through-holes 210 may not include any of the protrusions 1102.
[0095] In some embodiments, the plurality of protrusions 1102 can have a diameter substantially equal to the diameter of the through-hole 210. In other embodiments, the diameter of the plurality of protrusions 1102 can be smaller than the diameter of the through-hole 210.
[0096] In some embodiments, the plurality of protrusions 1102 of the second layer 204 may be configured to retain slough and other fluids removed from the tissue site within the protrusions 1102 while still inhibiting tissue granulation and tissue ingrowth. Additionally, in some embodiments, the plurality of fluid restrictors 214 in the second layer 204 may be configured to release slough and other fluids into the first layer 202.
[0097] FIG. 12 is a cross-sectional view of the second layer 204 of FIG. 11 taken along line 12-12, showing additional details that may be relevant to some embodiments. In some embodiments, the plurality of protrusions 1102 may have a substantially uniform height. In some embodiments, the plurality of protrusions 1102 may have a height equal to the thickness 220 of the first layer 202. In other embodiments, the height of the plurality of protrusions 1102 may be greater than the thickness 220 of the first layer 202. In yet other embodiments, the height of the plurality of protrusions 1102 may be less than the thickness 220 of the first layer 202. For example, the plurality of protrusions 1102 may be configured to extend into a portion of the plurality of through-holes 210 of the first layer 202. Additionally or alternatively, the plurality of protrusions 1102 may have varying heights.
[0098] FIG. 13 is an assembled view of another example of the dressing 104 of FIG. 1 , showing additional details that may be relevant to some embodiments. The dressing 104 may include a tissue interface 1308 and a cover 104. The tissue interface 1308 may be similar to the tissue interface 108 and operate as described above with respect to FIGS. 2-8 . For example, the tissue interface 1308 may include the first layer 202 and the second layer 204. In some embodiments, the tissue interface 1308 may also include a third layer 1302. The third layer 1302 may be configured to be coupled to the first side 206 of the first layer 202. The cover 110 may be configured to cover the third layer 1302. In some embodiments, the third layer 1302 may be a felt foam having a thickness less than or equal to the thickness 220 of the first layer 202.
[0099] 14 is a cross-sectional view of the assembled tissue interface 1308 of FIG. 13 taken along line 14-14, showing additional details that may be relevant to some embodiments. The tissue interface 108 may include a first layer 202, a second layer 204, and a third layer 1302. In some embodiments, the second layer 204 may have a first side 802 configured to be coupled to the second side 208 of the first layer 202. For example, the first side 802 of the second layer 204 may be bonded, glued, welded, or otherwise secured to the second side 208 of the first layer 202. In some embodiments, the second layer 204 may have a second side 804 opposite the first side 802 configured to be placed in direct contact with the tissue site 806. In some embodiments, the third layer 1302 may be configured to be coupled to the first side 206 of the first layer 202.
[0100] In some embodiments, the plurality of through-holes 210 may extend through the thickness 220 of the first layer 202 from the first side 206 to the second side 208 and operate in a manner similar to that described above with respect to Figures 2-10. In other embodiments, the first layer 202 and the third layer 1302 may be formed from a single layer of foam. In such embodiments, the through-holes 210 may comprise blind holes extending from the second side 208 of the second layer 202 toward the third layer 1302.
[0101] Also described herein are methods of manufacturing a dressing for a tissue site. A first layer can be provided, and a plurality of through-holes can be formed in the first layer. In some embodiments, the first layer can comprise a foam. In some embodiments, the method of forming the plurality of through-holes in the first layer can include die-cutting the foam to form a plurality of slugs and removing the plurality of slugs. In some embodiments, the method can further include felting the foam.
[0102] The method may further include providing a second layer. The second layer may be disposed adjacent to the first layer. In some embodiments, the second layer may be bonded to the first layer. For example, the second layer may be bonded to the first layer using an adhesive. A plurality of fluid restriction portions and a plurality of perforations may be formed in the second layer. Forming the plurality of perforations in the second layer may include aligning the plurality of perforations with the plurality of through-holes in the first layer. Additionally or alternatively, forming the plurality of perforations in the second layer may include thermoforming a plurality of protrusions in the second layer configured to extend into the plurality of through-holes in the first layer. In some embodiments, the plurality of through-holes in the first layer and the plurality of protrusions in the second layer may include a shape that is circular, elliptical, polygonal, and / or irregular.
[0103] Alternatively, other exemplary embodiments may describe a system for treating a tissue site. The system may include a dressing, a sealing member disposed over the dressing and configured to be sealed to tissue surrounding the tissue site, and a reduced pressure source configured to be fluidly coupled to the dressing through the sealing member. The dressing may include a debridement tool having a first side and a second side. In some embodiments, the debridement tool may have a plurality of openings extending through the debridement tool from the first side to the second side. In some embodiments, the debridement tool may include foam. The dressing may also include a contact layer configured to be disposed adjacent to the second side of the debridement tool. In some embodiments, the contact layer may have a plurality of fenestrations and a plurality of openings disposed therein. The plurality of openings may be configured to align with the plurality of openings in the debridement tool. In some embodiments, the plurality of openings may include a plurality of cylindrical protrusions configured to extend into the plurality of openings in the debridement tool.
[0104] In some embodiments, the contact layer can be bonded to the first side of the debridement tool. The contact layer can be bonded to the first side of the debridement tool using an adhesive. The adhesive can include a hot melt adhesive. In some embodiments, the contact layer can include a polymer film. In some embodiments, the polymer film can be hydrophilic. In some embodiments, the polymer film can be hydrophobic.
[0105] Methods for treating a tissue site are also described herein. A dressing can be placed at the tissue site. The dressing can include a first layer having a first side and a second side and a second layer configured to be positioned adjacent to the second side of the first layer. The first layer can include a plurality of through-holes extending through the first layer from the first side to the second side. The second layer can include a plurality of fluid restriction portions and a plurality of perforations. The plurality of perforations can be configured to align with the plurality of through-holes in the first layer. The method can also include fluidly coupling a negative pressure source to the dressing, applying negative pressure from the negative pressure source to the dressing, stretching a periphery of each of the plurality of perforations into the plurality of through-holes, creating a port in the first layer, and drawing a fluid through the port. In some embodiments, drawing a fluid through the port can include drawing a fluid through the second layer and into the first layer.
[0106] In some embodiments, the first layer may have a thickness extending from the first side to the second side. Each of the plurality of through-holes in the first layer may have a sidewall parallel to the thickness. Extending the periphery of each of the plurality of perforations into the plurality of perforations may include completely covering the sidewall with the periphery of each of the plurality of perforations.
[0107] In some embodiments, the plurality of perforations in the second layer may comprise a plurality of cylindrical protrusions. In such embodiments, extending a periphery of each of the plurality of perforations into the plurality of through-holes may include disposing each of the plurality of cylindrical protrusions into the plurality of through-holes. Additionally or alternatively, drawing fluid through the port may include collecting the fluid within the plurality of cylindrical protrusions.
[0108] The systems, devices, and methods described herein can provide significant advantages. For example, the second layer 204 can reduce or prevent exposure of the tissue site 806 to the first layer 202 while allowing the dressing 104 to debrid the tissue site, thereby inhibiting tissue in-growth into the first layer 202. The periphery of each of the plurality of perforations 216 in the second layer 204 can be extended into the through-holes 210 to completely cover the wall 212 of the first layer 202, creating a port through each of the through-holes 210. Thick slough and wound exudate can be removed from the tissue site through each port, while also inhibiting tissue in-growth into the first layer 202, allowing the dressing 104 to be worn for extended periods.
[0109] While illustrated in several exemplary embodiments, those skilled in the art will recognize that the systems, devices, and methods described herein are capable of various changes and modifications within the scope of the appended claims. Furthermore, the description of various alternatives using terms such as "or" does not require mutual exclusivity unless clearly required by context, and the indefinite articles "a" or "an" do not limit reference to a single case unless clearly required by context. Components may also be combined or excluded in various configurations for purposes of sale, manufacture, assembly, or use. For example, in some configurations, the dressing 104, the container 106, or both may be excluded or separated from other components for manufacture or sale. In other exemplary configurations, the controller 112 may also be manufactured, configured, assembled, or sold independently of other components.
[0110] The appended claims recite the novelty and inventive step of the above-described subject matter, but the claims may also encompass additional subject matter not specifically described in detail. For example, certain features, elements, or aspects may be omitted from the claims if they are not necessary to distinguish the novel and inventive features from those already known to those skilled in the art. Features, elements, and aspects described in the context of some embodiments may also be omitted, combined, or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention as defined by the appended claims.
Claims
1. 1. A dressing for treating a tissue site using negative pressure, comprising: a first layer having a first side and a second side; a plurality of through holes extending through the first layer from the first side to the second side; a second layer configured to be disposed adjacent to the second side of the first layer; a plurality of fluid restriction portions disposed on the second layer; a plurality of perforations disposed in the second layer and configured to be aligned with the plurality of through holes; Provided is a dressing.
2. The dressing of claim 1 , wherein at least a peripheral edge of each of said plurality of perforations is configured to extend into said plurality of through holes in response to a pressure gradient across said second layer.
3. 3. The dressing of claim 2, wherein the first layer has a thickness extending from the first side to the second side, each of the plurality of through holes forming a sidewall parallel to the thickness, and the peripheral edge of each of the plurality of perforations covering at least a portion of the sidewall.
4. The dressing of claim 3 , wherein a periphery of each of said plurality of perforations completely covers said sidewall.
5. The dressing of any one of claims 1 to 3, wherein each of the plurality of through holes has an effective diameter of about 5 millimeters to about 20 millimeters.
6. A dressing according to any preceding claim, wherein the plurality of through holes comprises a first row of through holes and a second row of through holes along the longitudinal length of the first layer.
7. The dressing of claim 6 , wherein one or more of the through-holes in the first row of through-holes are offset from the second row of through-holes.
8. A dressing according to any preceding claim, wherein the plurality of through holes are spaced between about 2 millimeters and about 10 millimeters center-to-center.
9. The dressing according to any one of claims 1 to 8, wherein a portion of the plurality of fluid restriction portions are aligned with a portion of the plurality of through holes.
10. A dressing according to any preceding claim, wherein each of the plurality of perforations is smaller than each of the plurality of through-holes.
11. A dressing according to any preceding claim, wherein each of the plurality of perforations is the same size as each of the plurality of through holes.
12. A dressing according to any preceding claim, wherein each of the plurality of perforations has an effective diameter smaller than the effective diameter of each of the plurality of through holes.
13. A dressing according to any preceding claim, wherein the plurality of perforations includes a plurality of protrusions configured to extend into the plurality of through holes.
14. A dressing according to any preceding claim, wherein the first layer is a manifold.
15. A dressing according to any preceding claim, wherein the first layer comprises a foam.
16. The dressing of claim 15 wherein the foam is compressed.
17. 16. The dressing of claim 15, wherein the foam is felted.
18. 20. The dressing of claim 17, wherein the foam has a hardness factor of about 3 to about 5.
19. The foam has a strength of at least about 18 lb / ft. 3 16. The dressing of claim 15 having a density of
20. 16. The dressing of claim 15, wherein the foam has an average pore size of from about 133 micrometers to about 600 micrometers.
21. 16. The dressing of claim 15, wherein the foam is a reticulated foam.
22. 16. The dressing of claim 15, wherein the foam is a compressed reticulated foam.
23. 16. The dressing of claim 15, wherein the foam is a reticulated foam that is felted.
24. A dressing according to any one of claims 1 or 4 to 23, wherein the first layer has a thickness extending from the first side to the second side.
25. 25. The dressing of claim 24, wherein the thickness of the first layer is from about 5 millimeters to about 15 millimeters.
26. A dressing according to any preceding claim, wherein the plurality of through holes are circular.
27. A dressing according to any preceding claim, wherein the plurality of through holes are elliptical.
28. A dressing according to any preceding claim, wherein the plurality of through holes are polygonal.
29. A dressing according to any preceding claim, wherein the plurality of through holes are irregular.
30. A dressing according to any preceding claim, wherein the second layer comprises a polymeric film.
31. 31. The dressing of claim 30, wherein the polymeric film is hydrophobic.
32. 31. The dressing of claim 30, wherein the polymeric film has a contact angle with water greater than 90 degrees.
33. 31. The dressing of claim 30, wherein the polymeric film is polyethylene.
34. 31. The dressing of claim 30, wherein the polymeric film is a polyethylene film having an areal density of less than about 30 grams per square meter.
35. A dressing according to any preceding claim, wherein the plurality of fluid restriction portions comprises a plurality of slots, each of the slots having a length of less than about 6 millimeters.
36. A dressing according to any preceding claim, wherein the plurality of fluid restriction portions comprises a plurality of slots, each of the slots having a width of less than about 2 millimeters.
37. A dressing according to any preceding claim, wherein the plurality of fluid restriction portions comprises a plurality of fenestrations in the second layer.
38. A dressing according to any preceding claim, wherein the plurality of fluid restriction portions comprises a plurality of slits in the second layer.
39. A dressing according to any preceding claim, wherein the second layer is configured for placement in direct contact with the tissue site.
40. A dressing according to any preceding claim, wherein the second layer is attached to the second side of the first layer.
41. A dressing according to any preceding claim, further comprising a cover configured to create a sealed space containing the first layer and the second layer at the tissue site.
42. 1. A method of manufacturing a dressing for a tissue site, comprising: Providing a first layer; forming a plurality of through holes in the first layer; providing a second layer; forming a plurality of fluid restriction portions in the second layer; forming a plurality of perforations in the second layer; disposing the second layer adjacent to the first layer; A method comprising:
43. 43. The method of claim 42, wherein forming the plurality of perforations in the second layer comprises aligning the plurality of perforations with the plurality of through holes.
44. 44. The method of claim 42 or 43, wherein disposing the second layer adjacent to the first layer comprises adhesively bonding the second layer to the first layer.
45. The method of any one of claims 42 to 44, wherein the first layer comprises a foam.
46. forming the plurality of through holes, die cutting the foam to form a plurality of slugs; removing the plurality of slags; and 46. The method of claim 45, comprising:
47. 47. The method of claim 45 or 46, further comprising felting the foam.
48. 48. The method of any one of claims 42-47, wherein forming the plurality of perforations comprises thermoforming a plurality of protrusions configured to extend into the plurality of through holes.
49. 49. The method of claim 48, wherein the plurality of through holes and the plurality of protrusions are circular.
50. 49. The method of claim 48, wherein the plurality of through holes and the plurality of protrusions are elliptical.
51. 49. The method of claim 48, wherein the plurality of through holes and the plurality of protrusions are polygonal.
52. 49. The method of claim 48, wherein the plurality of through holes and the plurality of protrusions are irregular.
53. 1. A system for treating a tissue site with reduced pressure, comprising: a debridement tool having a first side and a second side, the debridement tool comprising a plurality of openings extending therethrough from the first side to the second side; a contact layer configured to be positioned adjacent the second side of the debridement tool, the contact layer including a plurality of fenestrations and a plurality of apertures, the plurality of apertures configured to be aligned with the plurality of openings; A dressing comprising: a sealing member disposed over the dressing and configured to be sealed to tissue surrounding the tissue site; a reduced pressure source configured to be fluidly coupled to the dressing through the sealing member; A system comprising:
54. 54. The system of claim 53, wherein the interface layer is bonded to the first side of the debridement tool.
55. 55. The system of claim 54, wherein the interface layer is adhesively bonded to the first side of the debridement tool.
56. 56. The system of claim 55, wherein the adhesive comprises a hot melt adhesive.
57. The system of any one of claims 53 to 56, wherein the debridement tool comprises foam.
58. The system of any one of claims 53 to 57, wherein the contact layer comprises a polymer film.
59. 60. The system of claim 58, wherein the polymer film is hydrophilic.
60. 60. The system of claim 58, wherein the polymer film is hydrophobic.
61. 61. The system of any one of claims 53 to 60, wherein the plurality of openings comprises a plurality of cylindrical projections configured to extend into the plurality of openings.
